Contrasting Fos expression induced by acute reboxetine and fluoxetine in the rat forebrain: Neuroanatomical substrates for the antidepressant effect

Psychopharmacology

Volumn 177, Issue 3, 2005, Pages 289-295

  Miyata, Shinji ^a   Hamamura, Takashi ^a   Lee, Youmei ^b   Miki, Masahito ^c   Habara, Toshiaki ^d   Oka, Takuro ^a   Endo, Shiro ^a   Taoka, Hideki ^a   Kuroda, Shigetoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Mannari Hospital   (Japan)

^c Takaoka Hospital   (Japan)

^d Zikei Hospital   (Japan)

Author keywords

Antidepressants; Fluoxetine; Fos; Nucleus accumbens; Prefrontal cortex; Reboxetine

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PROTEIN FOS; REBOXETINE; SODIUM CHLORIDE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASCENDING AORTA; BRAIN REGION; CELL NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FOREBRAIN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NEUROANATOMY; NONHUMAN; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PERFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; TIME;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; FRONTAL LOBE; GENE EXPRESSION; GENES, FOS; IMMUNOHISTOCHEMISTRY; MALE; MORPHOLINES; NUCLEUS ACCUMBENS; PHOTOMICROGRAPHY; RATS; RATS, WISTAR;

EID: 12344268894     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-2072-7     Document Type: Article

References (46)

1. Alheid GF, Heimer L (1996) Theories of basal forebrain organization and the "emotional motor system". Prog Brain Res 107:461-484
2. Beck CH (1995) Acute treatment with antidepressant drugs selectively increases the expression of c-fos in the rat brain. J Psychiatr Neurosci 20:25-32
3. Belzung C, Le Guisquet AM, Barreau S, Calatayud F (2001) An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice. Behav Pharmacol 12:151-162
4. Berridge CW, Stratford TL, Foote SL, Kelley AE (1997) Distribution of dopamine beta-hydroxylase-like immunoreactive fibers within the shell subregion of the nucleus accumbens. Synapse 27:230-241
5. Biederman J, Spencer T (1999) Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234-1242
6. Bremner JD, Vythilingam M, Vermetten E, Nazeer A, Adil J, Khan S, Staib LH, Charney DS (2002) Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 51:273-279
7. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711
8. Carboni E, Tanda GL, Frau R, Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067-1070
9. Catalano G, Hakala SM, Catalano MC (2000) Sertraline-induced panic attacks. Clin Neuropharmacol 23:164-168
10. Cryan JF, Page ME, Lucki I (2002) Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur J Pharmacol 436:197-205
11. Delfs JM, Zhu Y, Druhan JP, Aston-Jones GS (1998) Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat. Brain Res 806:127-140
12. Dragunow M, Faull R (1989) The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods 29:261-265
13. Drevets WC (2000) Neuroimaging studies of mood disorders. Biol Psychiatry 48:813-829
14. Dubini A, Bosc M, Polin V (1997) Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 7:S49-S55; discussion S71-S73
15. Eriksson E (2000) Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin? Acta Psychiatr Scand Suppl 402:12-17
16. Eriksson E, Hedberg MA, Andersch B, Sundblad C (1995) The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 12:167-176
17. Faw B (2003) Pre-frontal executive committee for perception, working memory, attention, long-term memory, motor control, and thinking: a tutorial review. Conscious Cognit 12:83-139
18. Ferguson JM, Wesnes KA, Schwartz GE (2003) Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 18:9-14
19. George MS, Ketter TA, Post RM (1993) SPECT and PET imaging in mood disorders. J Clin Psychiatry 54:6-13
20. Gresch PJ, Sved AF, Zigmond MJ, Finlay JM (1995) Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 65:111-116
21. Hamamura T, Lee Y, Ohashi K, Fujiwara Y, Miki M, Suzuki H, Kuroda S (2000) A low dose of lithium chloride selectively induces Fos protein in the central nucleus of the amygdala of rat brain. Prog Neuropsychopharmacol Biol Psychiatry 24:285-294
22. 1A receptor-mediated serotonin augmentation on Fos immunoreactivity in rat brain. Eur J Pharmacol 455:109-115
23. Kasper S (1999) From symptoms to social functioning: differential effects of antidepressant therapy. Int Clin Psychopharmacol 14: S27-S31
24. Manji HK, Drevets WC, Charney DS (2001) The cellular neurobiology of depression. Nat Med 7:541-547
25. Massana J, Moller HJ, Burrows GD, Montenegro RM (1999) Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 14:73-80
26. Modigh K, Westberg P, Eriksson E (1992) Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 12:251-261
27. 2A/2C receptor function. Neuroscience 72:129-139
28. Moorman JM, Jackson A, Grahame-Smith DG, Leslie RA (1995) Induction of c-fos in rat forebrain by pharmacological manipulation of 5-hydroxytryptamine levels. Neuroscience 68:1089-1096
29. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22:389-395
30. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, Sydney
31. Pelosi L, Slade T, Blumhardt LD, Sharma VK (2000) Working memory dysfunction in major depression: an event-related potential study. Clin Neurophysiol 111:1531-1543
32. Rolls ET (2000) The orbitofrontal cortex and reward. Cereb Cortex 10:284-294
33. Rose JE, Woolsey CN (1948) The orbitofrontal cortex and its connections with the mediodorsal nucleus in rabbit, sheep, and cat. Res Publ-Assoc Nerv Ment Dis 27:210-232
34. Rouillard C, Bovetto S, Gervais J, Richard D (1996) Fenfluramine-induced activation of the immediate-early gene c-fos in the striatum: possible interaction between serotonin and dopamine. Brain Res Mol Brain Res 37:105-115
35. Sagar SM, Sharp FR, Curran T (1988) Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240:1328-1331
36. Salamone JD, Cousins MS, Snyder BJ (1997) Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev 21:341-359
37. Salchner P, Singewald N (2002) Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment. Neuropharmacology 43:1238-1248
38. Sasson Y, Iancu I, Fux M, Taub M, Dannon PN, Zohar J (1999) A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 9:191-196
39. Schoenbaum G, Setlow B (2001) Integrating orbitofrontal cortex into prefrontal theory: common processing themes across species and subdivisions. Learn Mem 8:134-147
40. Shu SY, Ju G, Fan LZ (1988) The glucose oxidase-DAB-nickel method in peroxidase histochemistry of the nervous system. Neurosci Lett 85:169-171
41. Singewald N, Salchner P, Sharp T (2003) Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry 53 275-283
42. Stephenson CP, Hunt GE, Topple AN, McGregor IS (1999) The distribution of 3,4-methylenedioxymethamphetamine "ecstasy"-induced c-fos expression in rat brain. Neuroscience 92:1011-1023
43. Stone EA, Zhang Y, John SM, Bing G (1991) c-Fos response to administration of catecholamines into brain by microdialysis. Neurosci Lett 133:33-35
44. Sumner BE, Cruise LA, Slattery DA, Hill DR, Shahid M, Henry B (2004) Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology 171:306-321
45. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L (1980) Clomipramine treatment of obsessive-compulsive disorder: I. A controlled clinical trial. Arch Gen Psychiatry 37:1281-1285
46. Williams RA, Hagerty BM, Cimprich B, Therrien B, Bay E, Oe H (2000) Changes in directed attention and short-term memory in depression. J Psychiatr Res 34:227-238